Detection of alzheimer's disease and other diseases using a photoaffinity labeling method
CA 2125787 C · Owner: The University Of Kentucky Research Foundation · Inventors: Haley, Boyd E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method for diagnosing a neurological disease comprising detecting a neurological disease-specific biochemical marker macromolecule within a sample of extracted cerebral spinal fluid is disclosed. In particular. a radioactively labeled photoaffinity probe is used to diagnose a neurological disease. For instance Alzheimer's , disease can be diagnosed by detecting a disease-specific protein having a molecular weight of about 42,000 daltons i.e. glutamine , synthetase.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 23, 1992 and granted March 27, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 23, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 23, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.